|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The glucocorticoid-insensitive hyperrresponsiveness in isolated human airways induced by IL-13 and IL-4 provides further evidence that the IL-4Rα pathway should be targeted as a new strategy for treatment of airway hyperresponsiveness in asthma.
|
31805312 |
2020 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab blocks the shared receptor component for IL-4 and IL-13, key drivers of type 2 inflammation, including IgE-mediated allergic inflammation in asthma.
|
31521831 |
2020 |
|
Asthma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Serum IL-5 and IL-13 decreased during climate treatment in asthma patients with high baseline levels.
|
31267528 |
2020 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The multifaceted roles of IL-4 and IL-13 in allergic disease development make IL-4Rα an attractive target for treatment strategies, and a neutralizing monoclonal antibody which antagonizes the effects of both IL-4 and IL-13 by blocking the interaction site found in the IL-4 receptor subunit α (IL-4Rα) has been successfully used to treat patients with moderate-to-severe AD.
|
31596502 |
2020 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Relevant literature concerning novel therapeutics for AD beyond targeted monoclonal antibodies antagonizing selectively interleukin (IL)-4 or IL-13 was obtained from a PubMed and clinicaltrials.gov search and summarized.
|
31622669 |
2020 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
This review provides an update on the role of IL-13 in AD and discusses the different strategies aimed at interfering with its biologic activity as well as their potential in a precision medicine approach in the management of AD.
|
31230370 |
2020 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
ILC2-derived IL-13 was sufficient for RSV-driven AHR, since reconstitution of wild-type ILC2 rescued RSV-driven AHR in IL-13-deficient mice.
|
31622507 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (T<sub>H</sub>2)-mediated allergic diseases such as asthma and atopic dermatitis.
|
31123339 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This initiates IL-5 and IL-13 production by ILC2, resulting in eosinophilic inflammation and airway hyperreactivity.
|
30516548 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, another important source of these type 2 cytokines, especially interleukin (IL)-5 and IL-13, are CD8<sup>+</sup> T-cells, which are increasingly proposed to play an important role in asthma pathogenesis, because they are abundant and are comparatively insensitive to corticosteroids.
|
31748421 |
2019 |
|
Asthma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Those with asthma had higher serum interferon (IFN)-α, but lower serum tumour necrosis factor, interleukin (IL)-5, IL-6, CXCL8, CXCL9, IL-10, IL-17 and CCL2 levels (all p<0.05); both groups had similar serum IL-13, total IgE, periostin and blood eosinophil gene expression levels.
|
31391224 |
2019 |
|
Asthma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Th2 asthma is mediated by allergen-specific Th2 cells, and eosinophils activated by Th2 cells via the secretion of interleukin (IL)-4, IL-5, and IL-13.
|
31776937 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Combined administration of anti-IL-13 and anti-IL-17A at individually sub-therapeutic doses limits asthma-like symptoms in a mouse model of Th2/Th17 high asthma.
|
30353972 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
With the evolution of novel biological therapies, patients, who do not-respond to conventional asthma therapy require novel biologic medications, such as anti-IgE, anti-IL-5 and anti-IL4/IL13 to control asthma symptoms.
|
31703832 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma.
|
31066001 |
2019 |
|
Asthma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
EBC and serum ezrin levels correlated with lung function in patients with asthma and serum ezrin levels were negatively correlated with serum IL-13 and periostin.
|
30290132 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Asthma is a chronic inflammatory airway disease associated with type 2 cytokines interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus overproduction, bronchial hyperresponsiveness (BHR), and immunogloubulin E (IgE) synthesis.
|
30995510 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).
|
30981576 |
2019 |
|
Asthma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that hsa_circ_0005519 may induce IL-13 and IL-6 expression by regulating hsa-let-7a-5p in CD4<sup>+</sup> T cells to affect asthma.
|
31148290 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Aim:</b> IL-13 is a biomarker of type 2 inflammation that plays a critical role in asthma.
|
31251105 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Ovalbumin induces natural killer cells to secrete Th2 cytokines IL‑5 and IL‑13 in a mouse model of asthma.
|
30816463 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Similar to Th2 cells, ILC2s produce IL-4, IL-5, and IL-13, among others, and are present in increased numbers in samples from patients with many allergic disorders including asthma and chronic rhinosinusitis (CRS).
|
30473412 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a 7-day prednisolone boost (0.5 mg/kg).
|
30940770 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab is a fully human monoclonal antibody that inhibits signalling of interleukin (IL)-4 and IL-13, key drivers of type 2 inflammation, and has been approved for use in atopic dermatitis and asthma.
|
31543428 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We showed that DN NKT cells with high CD38 expression produced IFN-γ, but not IL-17, IL-4, or IL-13, and inhibited development of AHR through contact-dependent suppression of helper CD4 T-cell proliferation.
|
29852257 |
2019 |